

November 25, 2013

Interprotein Corporation

Adoption of conformationally-constrained peptide (MicroAntibody) binding to vascular endothelial growth factor (VEGF) as a subject for A-STEP

Interprotein Corporation (President, Masato HOSODA; Headquarters: Osaka, Japan; hereinafter “Interprotein”) announced today that “Short-term generation of new molecular entity (NME) of conformationally-constrained peptide (MicroAntibody) inhibiting VEGF“, which had been applied in collaboration with Professor Ikuo FUJII, Osaka Prefecture University, was adopted as a subject of the second approval of “High-risk Challenge Type” of A-STEP (Adaptable & Seamless Technology Transfer Program through Target-driven R&D) by Japan Science and Technology Agency (JST) in 2013.

The subjects that were adopted in the second approval of “High-risk Challenge Type” of A-STEP in 2013 were listed in:

<http://www.jst.go.jp/pr/info/info995/besshi1.html> (in Japanese)

Contact:

Hirotsugu KOMATSU, Ph.D.

Interprotein Corporation

E-mail : info@interprotein.com